McKinsey failed to disclose conflicts of interest while simultaneously advising FDA and opioid manufacturers
Apr 27, 2022A House Oversight Committee investigation found that at least 22 McKinsey consultants were staffed at both the FDA and opioid manufacturers on related topics, sometimes simultaneously. In 2011, four consultants working on a $1.8M FDA drug safety contract were also working for Purdue Pharma on projects to persuade FDA of opioid safety, including writing scripts for Purdue to use in FDA meetings. McKinsey never disclosed these conflicts despite contractual obligations to do so.